Polimorfismi del recettore del frammento costante delle immunoglobuline G ed efficacia clinica del trattamento con Trastuzumab in pazienti affette da carcinoma mammario metastatico HER-2 positivo
Antonino Musolino
Università degli Studi di Parma. Dipartimento di Biologia evolutiva e funzionale
2009
Triple negative status and BRCA mutations in contralateral breast cancer: a population-based study.
Beatrice Bortesi , Daniela Boggiani , Nadia Naldi , Antonino Musolino
Acta bio-medica : Atenei Parmensis 87 ( 1) 54 -63
6
2016
My best choice after a round trip from illness.
Federico Quaini , Antonino Musolino , Benedetta Pellegrino , Chiara Tommasi
Acta bio-medica : Atenei Parmensis 88 ( 2) 196 -197
2017
Nab-paclitaxel after docetaxel hypersensitivity reaction: case report and literature review
Daniela Boggiani , Antonino Musolino , Benedetta Pellegrino , Chiara Tommasi
Acta Bio Medica : Atenei Parmensis 88 ( 3) 329 -333
18
2017
Immunoglobulin G fragment C receptor polymorphisms and response to trastuzumab-based treatment in patients with HER-2/neu-positive metastatic breast cancer
Diletta Laccabue , Beatrice Bortesi , Nadia Naldi , Antonino Musolino
Cancer Research 67 4188 -4188
5
2007
Efficacy of Margetuximab vs Trastuzumab in Patients With Pretreated ERBB2-Positive Advanced Breast Cancer: A Phase 3 Randomized Clinical Trial.
Mark D Pegram , Giuseppe Curigliano , Antonino Musolino , Katarína Petráková
JAMA Oncology 7 ( 4) 573 -584
195
2021
Abstract PS10-24: Infusion related reactions in the phase 3 SOPHIA trial of margetuximab + chemotherapy vs trastuzumab + chemotherapy in patients with pretreated HER2+ metastatic breast cancer
Mark D Pegram , Giuseppe Curigliano , Antonino Musolino , Timothy Pluard
Cancer Research
2021
Abstract PD10-04: Prognostic significance of germline BRCA mutations in patients with HER2-positive breast cancer. Epidemiological analysis in primary BRCA screens
Daniela Boggiani , Antonino Musolino , Claudia Omarini , Angelica Sikokis
Cancer Research
2021
Abstract PS4-33: Androgen receptors are highly expressed in HER2-positive breast cancers that achieve pCR to anti-HER2 monoclonal antibodies
Antonio Frassoldati , Daniela Boggiani , Antonino Musolino , Daniele Zanoni
Cancer Research
2021
Abstract OT-31-01: A phase II study to evaluate the efficacy and safety of pembrolizumab plus carboplatin in BRCA-related metastatic breast cancer: PEMBRACA trial
Luigi Marcheselli , Laura Cortesi , Antonino Musolino , Valentina Arcangeli
Cancer Research 81
2021
Luminal Breast Cancer: Risk of Recurrence and Tumor-Associated Immune Suppression.
Antonino Musolino , Marco Aiello , Karen Willard-Gallo , Benedetta Pellegrino
Molecular Diagnosis & Therapy 1 -16
2021
Abstract GS1-02: Phase 3 SOPHIA study of margetuximab + chemotherapy vs trastuzumab + chemotherapy in patients with HER2+ metastatic breast cancer after prior anti-HER2 therapies: second interim overall survival analysis
Hope S Rugo , Seock-Ah Im , Fatima Cardoso , Javier Cortes
Cancer Research 80
17
2020
Abstract P1-18-04: Phase 3 SOPHIA study of margetuximab + chemotherapy vs trastuzumab + chemotherapy in patients with HER2+ metastatic breast cancer after prior anti-HER2 therapies: Infusion time substudy results
William J Gradishar , Seock-Ah Im , Fatima Cardoso , Javier Cortes
Cancer Research 80
2020
p73 and p53 pathway in human breast cancers.
Cecilia Bozzetti , Rita Nizzoli , Antonino Musolino , Eugenia M. Martella
Journal of Clinical Oncology 25 ( 11) 1451 -1453
11
2007
Validation of the AJCC prognostic stage for HER2-positive breast cancer in the ShortHER trial
Maria Vittoria Dieci , Giancarlo Bisagni , Alba A. Brandes , Antonio Frassoldati
BMC Medicine 17 ( 1) 1 -9
6
2019
A breast cancer patient from Italy with germline mutations in both the BRCA1 and BRCA2 genes
Antonino Musolino , Nadia Naldi , Maria Michiara , Maria A. Bella
Breast Cancer Research and Treatment 91 ( 2) 203 -205
29
2005
Evaluation of HER-2/neu amplification and other biological markers as predictors of response to neoadjuvant anthracycline-based chemotherapy in primary breast cancer: the role of anthracycline dose intensity.
Cecilia Bozzetti , Antonino Musolino , Roberta Camisa , Giancarlo Bisagni
American Journal of Clinical Oncology 29 ( 2) 171 -177
37
2006
Accuracy and relative value of bone marrow aspiration in the detection of lymphoid infiltration in non-Hodgkin lymphoma
Antonino Musolino , Annamaria Guazzi , Rita Nizzoli , Michele Panebianco
Tumori 96 ( 1) 24 -27
11
2010
Early detection of recurrences in the follow-up of primary breast cancer in an asymptomatic or symptomatic phase.
Maria Antonietta Perrone , Antonino Musolino , Maria Michiara , Beatrice Di Biasio
Tumori 90 ( 3) 276 -279
17
2004
Molecular profile and clinical variables in BRCA1-positive breast cancers. A population-based study.
Antonino Musolino , Maria Michiara , Maria A. Bella , Nadia Naldi
Tumori 91 ( 6) 505 -512
12
2005